Waters Corporation Merges with BD to Transform Biosciences and Diagnostics Markets
- Waters Corporation merges with BD, creating a $17.5 billion entity in biosciences and diagnostics markets.
- The merger is expected to generate approximately $6.5 billion in revenue by 2025, enhancing Waters' growth potential.
- Waters aims to leverage BD's capabilities to drive innovation in diagnostic solutions and biopharmaceutical applications.
Waters Corporation and BD Unite to Enhance Biosciences Sector
Waters Corporation announces a significant merger with Becton, Dickinson and Company (BD), combining BD's Biosciences & Diagnostic Solutions with Waters' existing operations. This strategic alliance, valued at approximately $17.5 billion, positions the newly formed entity to become a formidable player in the biosciences and diagnostics markets. The merger is structured as a tax-efficient Reverse Morris Trust transaction, which is expected to create substantial value for both companies and their stakeholders.
The merger greatly expands Waters’ footprint in high-growth markets, tapping into an estimated total addressable market of around $40 billion, which is projected to grow at an annual rate of 5–7%. With the integration, the combined company anticipates a pro forma revenue of approximately $6.5 billion by 2025, alongside a projected adjusted EBITDA of about $2 billion. The merger is set to significantly enhance recurring annual revenue, with over 70% of revenue expected to come from this new arrangement. Over 80% of the total revenue is anticipated to arise from leading brands, solidifying the competitive edge of the merged entity.
In terms of financial synergies, the merger is poised to yield annual EBITDA synergies estimated at $345 million by 2030. This includes $200 million in cost synergies expected by the third year and $290 million in revenue synergies anticipated by the fifth year post-merger. The outlook for the combined organization remains optimistic, projecting mid- to high-single-digit revenue growth, an increase in adjusted operating margin of approximately 500 basis points, and adjusted EPS growth in the mid-teens over a five-year horizon. The companies will hold a joint conference call today at 8:00 AM ET to discuss the merger and its implications for the future.
In addition to the merger, this development marks a pivotal shift in the biosciences landscape, as Waters aims to leverage BD's established capabilities and customer base to drive innovation and enhance service offerings. The collaboration is expected to accelerate advancements in diagnostic solutions and biopharmaceutical applications, ultimately benefiting healthcare providers and patients alike.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

